4572Carna Biosciences4572 info
$2.76info-5.29%24h
Global rank25519
Market cap$47.35M
Change 7d-0.51%
YTD Performance-23.05%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Carna Biosciences (4572) Stock Overview

    Carna Biosciences, Inc., a clinical-stage biopharmaceutical company, discovers and develops drug therapies to treat unmet medical needs in Japan. Its products include kinase proteins, substrates, kinase protein assay kits, and stable cell lines, as well as biotinylated kinases. The company also offers profiling, NanoBRET TE intracellular kinase cell-based assay, protein detection and interaction, live-cell kinase assay, and tyrosine kinase cell-based assay services. It also focuses on developing products for the treatment of various diseases, such as AS-0141, an orally bioavailable small molecule inhibitor of CDC7 kinase that is in preclinical trials to treat cancer; AS-0871, a small molecule drug for inflammatory and immune disorders, which is in Phase 1 clinical trials; and AS-1763, an orally bioavailable and non-covalent inhibitor for the treatment of chronic lymphocytic leukemia and other B cell malignancies that is in preclinical trials. The company has collaborations with Johnson & Johnson, Sierra Oncology, Sumitomo Dainippon Pharma, Gilead Sciences, and BioNova Pharmaceuticals. Carna Biosciences, Inc. was incorporated in 2003 and is based in Kobe, Japan.

    4572 Stock Information

    Symbol
    4572
    Address
    BMA, 1-5-5 Minatojima-MinamimachiKobe, 650-0047Japan
    Founded
    -
    Trading hours
    -
    Website
    https://www.carnabio.com
    Country
    πŸ‡―πŸ‡΅ Japan
    Phone Number
    81 78 302 7039

    Carna Biosciences (4572) Price Chart

    -
    Value:-

    Carna Biosciences Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $2.76
    N/A
    Market Cap
    $47.35M
    N/A
    Shares Outstanding
    17.14M
    N/A
    Employees
    65.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org